Akebia Therapeutics Statistics
Share Statistics
Akebia Therapeutics has 262.64M
shares outstanding. The number of shares has increased by 24.64%
in one year.
| Shares Outstanding | 262.64M |
| Shares Change (YoY) | 24.64% |
| Shares Change (QoQ) | 19.73% |
| Owned by Institutions (%) | 32.25% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 42,676 |
| FTD / Avg. Volume | 0.85% |
Short Selling Information
The latest short interest is 19.72M, so 7.51% of the outstanding
shares have been sold short.
| Short Interest | 19.72M |
| Short % of Shares Out | 7.51% |
| Short % of Float | 7.59% |
| Short Ratio (days to cover) | 4.39 |
Valuation Ratios
The PE ratio is -5.77 and the forward
PE ratio is 162.
Akebia Therapeutics's PEG ratio is
-0.32.
| PE Ratio | -5.77 |
| Forward PE | 162 |
| PS Ratio | 2.5 |
| Forward PS | 1.3 |
| PB Ratio | -8.15 |
| P/FCF Ratio | -9.85 |
| PEG Ratio | -0.32 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Akebia Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.41,
with a Debt / Equity ratio of -0.97.
| Current Ratio | 1.41 |
| Quick Ratio | 1.21 |
| Debt / Equity | -0.97 |
| Debt / EBITDA | -3.47 |
| Debt / FCF | -1.17 |
| Interest Coverage | -2.78 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $884,972.38 |
| Profits Per Employee | $-383,480.66 |
| Employee Count | 181 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 3.89 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 204.42% in the
last 52 weeks. The beta is 0.88, so Akebia Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.88 |
| 52-Week Price Change | 204.42% |
| 50-Day Moving Average | 2.32 |
| 200-Day Moving Average | 1.92 |
| Relative Strength Index (RSI) | 79.94 |
| Average Volume (20 Days) | 5,002,503 |
Income Statement
In the last 12 months, Akebia Therapeutics had revenue of 160.18M
and earned -69.41M
in profits. Earnings per share was -0.33.
| Revenue | 160.18M |
| Gross Profit | 97M |
| Operating Income | -50.47M |
| Net Income | -69.41M |
| EBITDA | -13.72M |
| EBIT | -51.23M |
| Earnings Per Share (EPS) | -0.33 |
Full Income StatementBalance Sheet
The company has 51.87M in cash and 47.64M in
debt, giving a net cash position of 4.23M.
| Cash & Cash Equivalents | 51.87M |
| Total Debt | 47.64M |
| Net Cash | 4.23M |
| Retained Earnings | -1.68B |
| Total Assets | 310.19M |
| Working Capital | 112.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -40.66M
and capital expenditures -33K, giving a free cash flow of -40.69M.
| Operating Cash Flow | -40.66M |
| Capital Expenditures | -33K |
| Free Cash Flow | -40.69M |
| FCF Per Share | -0.19 |
Full Cash Flow StatementMargins
Gross margin is 60.56%, with operating and profit margins of -31.51% and -43.33%.
| Gross Margin | 60.56% |
| Operating Margin | -31.51% |
| Pretax Margin | -43.33% |
| Profit Margin | -43.33% |
| EBITDA Margin | -8.57% |
| EBIT Margin | -31.51% |
| FCF Margin | -25.4% |
